Is Haleos Labs Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Haleos Labs Ltd (HALEOSLABS.NS) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Haleos Labs Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Haleos Labs Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Haleos Labs Ltd?

Muslim investors may consider investing in Haleos Labs Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Haleos Labs Ltd classified as HALAL?

Musaffa determines the Shariah status of Haleos Labs Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Haleos Labs Ltd updated?

The Shariah compliance status of Haleos Labs Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Haleos Labs Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Haleos Labs Ltd?

You can check the latest Shariah compliance status of Haleos Labs Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Haleos Labs Ltd HALEOSLABS.NS

₹1,555.80 ₹46.20 (2.88%) 1D

Last Updated: May 15, 12:00 AM·NSE

HALEOSLABS.NS Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: March 12, 2026

Report Source: 2026 3rd Quarter Report

Haleos Labs Ltd. Stock Analysis HALEOSLABS.NS

India Health Care Nano Cap Report: Q3, 2026

Haleos Labs Ltd. engages in manufacturing and selling of active pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 592 full-time employees. The company went IPO on 2017-08-17. The firm's API products include Ranitidine Hydrochloride (Form-2) USP / Ph. Eur / IP, Famotidine USP / Ph. Eur / IP, Sildenafil Citrate USP / Ph. Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph. Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. Its intermediate offerings include Ranitidine HCl Intermediates, Rizatriptan Intermediates and Imidapril Intermediates. The firm's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center is at Sanath Nagar in Hyderabad. The firm's wholly owned subsidiary is Mahi Drugs Private Limited.

Key Statistics of Haleos Labs Ltd (HALEOSLABS.NS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

₹1,555.80₹1,619.40

Today's Open

₹1,602.00

Volume

1012.00

P/E Ratio (TTM)

24.66

52 Week Range

₹1,067.00₹1,774.00

Market Cap

4.61B

Avg. Volume

2885.91

Dividend Yield

0.09%

Financial Metrics & Statements of Haleos Labs Ltd (HALEOSLABS.NS)

FAQ's for Haleos Labs Ltd (HALEOSLABS.NS)

According to Musaffa’s Shariah screening methodology, Haleos Labs Ltd (HALEOSLABS.NS) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.